Quantificare v. Canfield Scientific: Federal Circuit Affirms Unpatentability of 3D Imaging Patent
Quantificare SA’s appeal to the Federal Circuit failed after 676 days, with the court affirming the unpatentability of US10165253B2 — a patent covering device and method technology for 3D face and body reconstruction. The ruling leaves Canfield Scientific free of infringement risk on this patent and extinguishes Quantificare’s enforcement position at the appellate level.
Federal Circuit closes the door on Quantificare’s 3D imaging patent rights
Quantificare SA, a French medical imaging company, brought an appeal before the U.S. Court of Appeals for the Federal Circuit (Case No. 23-1918) challenging a lower tribunal’s finding that US10165253B2 — covering a device and method to reconstruct face and body in 3D — was unpatentable. The appeal was filed on 19 May 2023 and opposed by Canfield Scientific, Inc., a competing provider of clinical and aesthetic imaging systems. The patent in suit, filed under application number US16/035935, sits at the intersection of 3D imaging, photogrammetry, and medical-aesthetic documentation technology.
On 25 March 2025, the Federal Circuit issued its judgment affirming the unpatentability determination. An affirmance at this level means the appellate court found no reversible legal error in the tribunal below — the invalidity ruling stands as a final, binding disposition. For Quantificare, this exhausts federal appellate review short of a petition for certiorari to the Supreme Court, a rarely granted remedy. For Canfield Scientific, the outcome removes US10165253B2 as an enforceable instrument and eliminates any continuing infringement exposure tied to this patent.
The 676-day duration from filing to decision is notably longer than a typical Federal Circuit appeal, which may suggest the case involved substantive technical or legal complexity warranting extended briefing or consideration. The basis of termination — recorded simply as ‘Unpatentable’ — confirms the merits were fully adjudicated rather than resolved on procedural grounds. What remains undisclosed from the public record is whether the patentability challenge rested on prior art, subject-matter eligibility under § 101, or another statutory basis, and whether any claims survived in modified form.
Filing to Unpatentable in 676 days
676 days — longer than the median Federal Circuit appeal (~400 days), suggesting substantive briefing complexity
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the lower decision survives intact
When the Federal Circuit issues an AFFIRMED judgment, it signals the panel found no reversible error — legal or factual — in the tribunal below. The unpatentability determination is now a final, binding ruling. It cannot be relitigated in any U.S. federal court unless Quantificare successfully petitions the Supreme Court for certiorari, a remedy granted in fewer than 1–2% of cases. The patent is, for practical purposes, extinguished.
Finality confirmedQuantificare loses enforceability of its 3D imaging patent
For Quantificare SA, the affirmance is a definitive adverse outcome. US10165253B2 can no longer be asserted against Canfield Scientific or, as a practical matter, any other party — a finding of unpatentability has broad estoppel effects. The company’s ability to monetise or license this particular IP asset is eliminated. Any product roadmap or licensing strategy that depended on this patent’s enforceability must now be reassessed against the remaining portfolio.
Patent extinguishedCanfield Scientific achieves full clearance on this patent
Canfield Scientific secured the most commercially durable outcome available: an appellate-level affirmance of unpatentability. The company faces no further litigation risk from US10165253B2 and can operate its 3D imaging product lines without exposure to this patent’s claims. The Federal Circuit’s ruling also raises the bar against any future attempt by Quantificare to assert related technology through continuation or divisional patents that share the same specification, as prior art findings typically carry broad estoppel.
Cleared at appellate level3D medical imaging sector sees key patent removed from the landscape
The invalidation of US10165253B2 reshapes freedom-to-operate considerations for any company developing 3D face and body reconstruction technology for clinical or aesthetic applications. Competitors and new entrants previously navigating around this patent’s claims now have expanded design freedom. However, Quantificare may hold related patents covering adjacent methods or system architectures — thorough FTO analysis remains advisable. The ruling also reinforces the Federal Circuit’s rigorous patentability scrutiny in medical imaging innovation.
FTO landscape widensFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Quantificare, SA | Company | French medical imaging company — holder of US10165253B2 covering 3D face and body reconstructionSearch in Eureka ↗ |
| Defendant | Canfield Scientific, Inc. | Company | Canfield Scientific, Inc. — U.S. provider of clinical and aesthetic skin and body imaging systemsSearch in Eureka ↗ |
| Plaintiff counsel | Kevin Reiner | Attorney | Counsel for Quantificare, SASearch in Eureka ↗ |
| Plaintiff counsel | Mark D. Giarratana | Attorney | Counsel for Quantificare, SASearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Quantificare, SASearch in Eureka ↗ |
| Defendant counsel | Chelsea Murray | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Isha S. Shah | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael R. Weiner | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas Lee Duston | Attorney | Counsel for Canfield Scientific, Inc.Search in Eureka ↗ |
| Defendant law firm | Marshall Gerstein & Borun LLP | Law Firm | Representing Canfield Scientific, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a merits affirmance with no remand, meaning the lower tribunal’s unpatentability finding is final and unreviewable at this level. The brevity of the disposition language is typical of Federal Circuit summary affirmances, where the panel finds no substantial question warranting extended opinion. For Quantificare, no further appellate avenue exists in the federal system short of a Supreme Court certiorari petition. For Canfield Scientific, the ruling provides the strongest possible clearance position.
US10165253B2 — Device and Method to Reconstruct Face and Body in 3D
US10165253B2, filed under application number US16/035935, protects a device and method for reconstructing the human face and body in three dimensions. The patent sits within the technical domain of computational imaging, photogrammetry, and 3D surface modelling — technologies with significant application in medical aesthetics, dermatology, plastic surgery planning, and clinical documentation. The ‘B2’ designation confirms this is a granted utility patent that underwent post-grant examination, consistent with its involvement in an invalidity proceeding.
Strategically, US10165253B2 represented Quantificare’s effort to protect a core capability in clinical 3D imaging — a market where Canfield Scientific is a principal commercial competitor. Patents covering reconstruction methods in this space are highly valuable because they can block competitors from offering equivalent imaging workflows rather than merely specific hardware configurations. The Federal Circuit’s affirmance of unpatentability eliminates this competitive moat, and companies active in medical imaging, aesthetic documentation, or AI-driven body analysis should reassess both their FTO position and whether Quantificare holds surviving related assets.
Should your team run an FTO analysis referencing US10165253B2?
Any company developing or commercialising 3D face and body reconstruction systems — particularly for medical aesthetics, dermatology, cosmetic surgery planning, or clinical photography — should be aware that US10165253B2 has been affirmed as unpatentable. This patent no longer presents a direct infringement risk. However, Quantificare may hold continuation or divisional patents with overlapping claim scope that remain in force. R&D and product teams building imaging reconstruction pipelines should verify that no related family members cover their specific implementation.
PatSnap Eureka’s FTO Search Agent enables product teams to run a structured freedom-to-operate analysis against US10165253B2’s patent family — identifying live continuations, foreign equivalents, and claim-level overlaps with your product’s technical architecture. By mapping the full priority chain from US16/035935, Eureka surfaces residual risk assets that may not appear in a simple number-based search, giving IP counsel and R&D leaders a complete clearance picture before product launch or licensing negotiations.
Run a freedom-to-operate analysis on US10165253B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in 3D imaging and medical device patentability
Explore Federal Circuit cases involving patentability challenges to 3D imaging, medical reconstruction, and clinical photography technology — comparable to Case No. 23-1918.
What this case signals for the medical 3D imaging IP landscape
The Federal Circuit’s affirmance clarifies enforceability risk in 3D face and body reconstruction technology — with direct implications for competitors and licensors.
Unpatentability affirmances carry estoppel risk across related patents
A Federal Circuit affirmance of unpatentability does not automatically cancel related applications, but the underlying prior art or § 101 reasoning can be leveraged in IPR petitions or litigation involving continuation patents sharing the same specification. Companies holding or licensing technology adjacent to US10165253B2 should audit their portfolio for exposure to the same invalidity arguments.
Canfield Scientific’s defence strategy validates IPR/post-grant as a primary tool
The case’s resolution through a patentability invalidity action — rather than non-infringement — is consistent with a defendant-side strategy of attacking the patent root rather than designing around it. For companies facing 3D imaging patent assertions, this outcome suggests post-grant challenges at the PTAB remain a viable and effective path, particularly where the patent’s claims may be vulnerable to prior art in the photogrammetry or structured-light imaging space.
Quantificare v Canfield — key questions answered
The Federal Circuit affirmed the lower tribunal’s finding that US10165253B2 — covering a device and method to reconstruct face and body in 3D — was unpatentable. The judgment, issued on 25 March 2025, is a merits affirmance with no remand, making the unpatentability determination final at the federal appellate level.
US10165253B2 is a U.S. utility patent filed under application number US16/035935, held by Quantificare SA. It covers a device and method for reconstructing the human face and body in three dimensions — technology used in medical aesthetics, dermatology, plastic surgery planning, and clinical imaging documentation.
A termination basis of ‘Unpatentable’ indicates the patent’s claims were found to fail patentability requirements — typically under 35 U.S.C. §§ 101, 102, 103, or 112. In this context, the lower tribunal’s invalidity determination was affirmed by the Federal Circuit, meaning the patent is extinguished and cannot be enforced against any party.
No. Following the Federal Circuit’s affirmance of unpatentability, US10165253B2 is no longer enforceable. Quantificare’s only remaining avenue would be a petition for certiorari to the U.S. Supreme Court, which is granted in fewer than 2% of cases. The company may, however, hold other patents in the same family that were not subject to this proceeding.
The invalidation of US10165253B2 widens design freedom for companies developing 3D face and body reconstruction systems. However, Quantificare may hold continuation or divisional patents sharing the same priority date as US16/035935 that remain in force. A thorough FTO analysis covering the full patent family is advisable before commercialising overlapping technology.
PatSnap Eureka searches patents and litigation data to answer instantly.